

October 28, 2019



Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board

SAN JOSE, Calif., Oct. 28, 2019 /PRNewswire/ -- [Anixa Biosciences, Inc.](#) (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the appointment of Emanuele Ostuni, Ph.D. to its Scientific Advisory Board.



Dr. Ostuni is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees all commercialization aspects of the division's portfolio in Europe, including Kymriah, the first FDA-approved CAR-T cell therapy. Dr. Ostuni has been with Novartis since 2012 in various executive roles. Previously he held positions with Nano Terra, McKinsey & Co., and Surface Logix. Dr. Ostuni was also the co-founder of Enumeral Biomedical and served on its board of directors through its public listing in 2014. Dr. Ostuni earned a Ph.D. in Physical Chemistry from Harvard University and a bachelor's and master's degree in Chemistry from Georgetown University.

"We are pleased to have such an accomplished and experienced leader in the cell therapy field join our Scientific Advisory Board," stated Amit Kumar, Ph.D., Chief Executive Officer of Anixa. "Anixa seeks to add relevant expertise to its advisory board as we near the beginning of clinical trials for our products, including our CAR-T therapy for ovarian cancer, which is partnered with the Moffit Cancer Center and the Wistar Institute. Dr. Ostuni's experience in CAR-T cell therapy development, partnering and commercialization will be invaluable to us as we move our therapy forward."

"I look forward to working with Anixa's broad portfolio of technologies, given its potential to improve the lives of many cancer patients, and in particular its CAR-T approach for treating

solid tumors," commented Dr. Ostuni. "I am excited to offer my experience and expertise to advance this novel approach through the clinical process and, should the data prove favorable, enable the millions of women diagnosed with ovarian cancer the opportunity to benefit from this potentially groundbreaking therapy."

About Anixa Biosciences, Inc.

Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α -Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

[Tiberend Strategic Advisors, Inc.](#)

Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149

Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686

[releases/anixa-biosciences-names-novartis-executive-dr-emanuele-ostuni-to-scientific-advisory-board-300945852.html](https://www.businesswire.com/news/home/20190425005231/en/Anixa-Biosciences-Names-Novartis-Executive-Dr-Emanuele-Ostuni-to-Scientific-Advisory-Board)

SOURCE Anixa Biosciences, Inc.